Actor portrayals

The first and only silencer for ATTR-CM and hATTR-PN

Rapidly knocks down TTR

In a clinical study, AMVUTTRA® (vutrisiran) reduced TTR at 6 weeks after the first dose and maintained
reductions with continued treatment.

Results shown are from the ATTR-CM study. Similar reductions were seen in the hATTR-PN study (at 3 weeks after the first dose and with 1½ years of treatment).
Individual results may vary.

How AMVUTTRA works: the science behind the silencer

Watch video

Reduces TTR at the source

As a silencer, AMVUTTRA suppresses TTR production in the liver—where most of it is made.

AMVUTTRA works in the liver to reduce the amount of TTR produced and circulated in the blood.

Less TTR in the blood means there's less that can misfold and build up as amyloid deposits in the body.

With fewer amyloid deposits building up, the progression of ATTR-CM and hATTR-PN may be slowed.

Build your personalized discussion guide

This Doctor Discussion Guide can help you prepare for your next appointment and discuss your treatment goals.

If you're the caregiver of someone with ATTR-CM or hATTR-PN, complete this guide together.

Or, you can download a version to print and fill out.

Actor portrayal

Common questions about how ATTR-CM and hATTR-PN medications work

These are answers to commonly asked questions. Talk to your doctor for more information.

ATTR-CM treatment options work in different ways to reduce misfolded TTR proteins from building up in the body and causing damage. There are currently two main types of FDA-approved medications for ATTR-CM: silencers and stabilizers. Silencers work in the liver to reduce TTR production, so fewer proteins get made. Stabilizers work in the blood to keep TTR from misfolding, so fewer proteins break apart. FDA-approved treatment options for hATTR-PN include silencers.

While silencers and stabilizers are not new therapies for ATTR-CM, research and development of these types of therapies, as well as those that work differently, are ongoing.

Have a conversation with your doctor about available treatment options for ATTR-CM and hATTR-PN and how soon they may work. People may respond to treatment differently.

Important Safety Information

What are the most important things I should know about AMVUTTRA® (vutrisiran)?

AMVUTTRA can cause low vitamin A levels

Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.

Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.

What are the common side effects of AMVUTTRA?

The most common side effects of AMVUTTRA were pain in the arms or legs, pain in the joints, shortness of breath, and low vitamin A levels.

These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Indications

What is AMVUTTRA?

AMVUTTRA is a prescription medicine that treats the:

  • cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce heart-related death, hospital stays and urgent visits.
  • polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

ATTR amyloidosis
with cardiomyopathy (also known
as ATTR cardiac amyloidosis)​

hereditary ATTR
amyloidosis with polyneuropathy

transthyretin

transthyretin
amyloidosis

Kansas City Cardiomyopathy
Questionnaire

6-minute walk test

modified Neuropathy
Impairment Score +7

Quality of Life-Diabetic
Neuropathy